Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Hematology"
DOI: 10.1007/s12185-019-02638-6
Abstract: A proportion of patients with immune thrombocytopenic purpura are refractory to multiple therapies including thrombopoietin-receptor agonists (TPO-RA). We report 10 patients who did not respond to a TPO-RA until the addition of a glucocorticoid. These… read more here.
Keywords: glucocorticoids promote; receptor agonists; promote response; thrombopoietin receptor ... See more keywords
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations.
Sign Up to like & getrecommendations! Published in 2019 at "Blood reviews"
DOI: 10.1016/j.blre.2019.100647
Abstract: Thrombopoietin receptor agonists (TPO-RAs) are currently indicated for continuous treatment of chronic primary immune thrombocytopenia (ITP). However, there is growing evidence that TPO-RAs can also trigger sustained response in 10-30% of cases after treatment tapering… read more here.
Keywords: tapering discontinuation; treatment; discontinuation; thrombopoietin receptor ... See more keywords
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
Sign Up to like & getrecommendations! Published in 2021 at "Blood reviews"
DOI: 10.1016/j.blre.2021.100909
Abstract: Thrombopoietin regulates platelet production through activation of the thrombopoietin receptor (TPO-R). TPO-R agonists (TPO-RAs) are available to treat thrombocytopenia in chronic immune thrombocytopenia (ITP), chronic liver disease (CLD) patients who are undergoing a procedure, severe… read more here.
Keywords: thrombopoietin; avatrombopag; tpo; thrombopoietin receptor ... See more keywords
Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment
Sign Up to like & getrecommendations! Published in 2019 at "Platelets"
DOI: 10.1080/09537104.2017.1411586
Abstract: Abstract Bone marrow (BM) fibrosis is a potential side effect of thrombopoietin receptor agonist (TPO-RA) treatment. We aimed to investigate stromal seromarker profiles and growth factors in order to elucidate pathogenic and dynamic aspects of… read more here.
Keywords: marrow fibrosis; fibrosis; treatment; thrombopoietin receptor ... See more keywords
Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists
Sign Up to like & getrecommendations! Published in 2019 at "Platelets"
DOI: 10.1080/09537104.2019.1585527
Abstract: Abstract MicroRNAs (miRNAs) are small non-coding RNAs involved in the regulation of gene expression. Dysregulated expression of several miRNAs has been found in primary immune thrombocytopenia (ITP) suggesting that miRNAs are likely involved in the… read more here.
Keywords: treatment; treatment thrombopoietin; mir; receptor agonists ... See more keywords
Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany.
Sign Up to like & getrecommendations! Published in 2021 at "Hematology"
DOI: 10.1080/16078454.2021.1974203
Abstract: OBJECTIVE To assess real-world treatment patterns in patients with immune thrombocytopenia (ITP) who received thrombopoietin receptor agonists (TPO-RAs) in Germany. METHODS This was a longitudinal, retrospective study using anonymized patient-level data (IQVIA healthcare prescription database,… read more here.
Keywords: use; treatment; immune thrombocytopenia; prescription ... See more keywords
Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2023.2201428
Abstract: ABSTRACT Introduction Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer treatment, frequently leading to reduced relative dose intensity, and is associated with reduced survival. Given the lack of FDA-approved therapies for CIT, thrombopoietin receptor… read more here.
Keywords: chemotherapy induced; tpo ras; thrombopoietin receptor; induced thrombocytopenia ... See more keywords
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.15573
Abstract: Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6‐month, multicentre, randomised, double‐blind, parallel‐group Phase 3 study, with an open‐label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day)… read more here.
Keywords: phase; chronic immune; receptor agonist; immune thrombocytopenia ... See more keywords
Thrombopoietin receptor agonists increase splenic regulatory T‐cell numbers in immune thrombocytopenia
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18309
Abstract: Thrombopoietin receptor agonists (TPO‐RA) are a valid therapy for immune thrombocytopenia (ITP), due to megakaryocyte stimulation and (poorly characterised) immune‐modulatory effects. The spleen is pivotal in the pathogenesis of ITP, yet little is known on… read more here.
Keywords: receptor agonists; thrombopoietin receptor; immune thrombocytopenia; splenic regulatory ... See more keywords
Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18332
Abstract: Therapeutic management of patients with immune thrombocytopenia (ITP) remains challenging; however, thrombopoietin receptor agonists (TPO‐RAs) have revolutionised the treatment landscape of ITP. It is increasingly hypothesised that TPO‐RAs may have an immune modulatory role and… read more here.
Keywords: receptor agonists; patients immune; immune thrombocytopenia; thrombopoietin receptor ... See more keywords
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Advances in Hematology"
DOI: 10.1177/2040620719837906
Abstract: Primary immune thrombocytopenia (ITP) is a bleeding disorder that conventionally has been treated with steroids or other immunosuppressive treatments. The introduction of thrombopoietin receptor agonists (TPO-RAs), which increase platelet production, dramatically changed the treatment landscape… read more here.
Keywords: alternate tpo; tpo; primary immune; immune thrombocytopenia ... See more keywords